Evidence map›Paper›PMID 41120744›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026

The effects of tetrahydrocannabinol and cannabidiol on sleep in cancer patients.

Apoorva C Reddy, John M Hampton, Susan J Park, Faith Dickerson, Betty Chewning, Natalie Schmitz, Kristine Kwekkeboom, Heather Neuman, Amy Trentham-Dietz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Apoorva C ReddyDepartment of Surgery, School of Medicine and Public Health, University of Wisconsin-Madison, 750 Highland Avenue, Madison, WI, 53726, USA. reddy@surgery.wisc.edu.ORCID http://orcid.org/0000-0001-6966-7282
John M HamptonDepartment of Population Health Sciences and Carbone Cancer Center, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, USA.
Susan J ParkAnalytics Division, Minnesota Office of Cannabis Management, Saint Paul, USA.
Faith DickersonDepartment of Surgery, School of Medicine and Public Health, University of Wisconsin-Madison, 750 Highland Avenue, Madison, WI, 53726, USA.
Betty ChewningSchool of Pharmacy, University of Wisconsin-Madison, Madison, USA.
Natalie SchmitzSchool of Pharmacy, University of Wisconsin-Madison, Madison, USA.
Kristine KwekkeboomSchool of Nursing, University of Wisconsin-Madison, Madison, USA.
Heather NeumanDepartment of Surgery, School of Medicine and Public Health, University of Wisconsin-Madison, 750 Highland Avenue, Madison, WI, 53726, USA.
Amy Trentham-DietzDepartment of Population Health Sciences and Carbone Cancer Center, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, USA.

Funding

Division of Cancer Prevention, National Cancer Institute P30CA014520Division of Cancer Prevention, National Cancer Institute T32CA090217
6 · The paper itself

Abstract

backgroundDespite limited research, cancer patients are opting for compounds found in cannabis, like tetrahydrocannabinol (THC) and cannabidiol (CBD), to improve their sleep. The purpose of this study was to examine the therapeutic value of cannabis for sleep.

methodsPatient-reported symptom responses were obtained from 1962 cancer patients enrolled in the Minnesota Medical Cannabis Program (MMCP) from 2015 to 2023. Multivariable logistic and linear regression models were used to evaluate the associations between changes in reported sleep disturbance scores and the dose of THC, the dose of CBD, and the cannabinoid ratio (THC:CBD). Logistic and linear regression models were adjusted for sex, age, race, ethnicity, body mass index, and MMCP enrollment fee category. Linear regression models were additionally adjusted for baseline sleep disturbance score.

resultsCompared to the highest quintile category of CBD dose, lower dose quintiles were 29-35% less likely to be associated with at least a 30% improvement in sleep disturbance scores. Sleep disturbance scores improved by 1.87 points on a 0-10 ordinal scale for cancer patients with CBD doses in the top quintile, and approximately 1.5 points for doses in lower quintiles. THC and THC:CBD doses were not consistently related to changes in sleep disturbance scores.

conclusionHigher CBD doses may be associated with clinically meaningful improvements in sleep in cancer patients enrolled in a medical cannabis program.

Indexed as

CannabidiolDronabinolMedical MarijuanaNeoplasmsSleepSleep Wake DisordersAdultAgedFemaleHumansMaleMiddle AgedCannabidiolDronabinolMedical MarijuanaCancerCannabisLongitudinal studiesPalliative careSleep

Identifiers

PMID41120744
PMCPMC13009030

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.